These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34531262)

  • 21. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
    Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J
    Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [
    Glorie D; Verhaeghe J; Miranda A; De Lombaerde S; Stroobants S; Staelens S
    EJNMMI Res; 2020 Nov; 10(1):140. PubMed ID: 33185747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synaptic density in healthy human aging is not influenced by age or sex: a
    Michiels L; Delva A; van Aalst J; Ceccarini J; Vandenberghe W; Vandenbulcke M; Koole M; Lemmens R; Laere KV
    Neuroimage; 2021 May; 232():117877. PubMed ID: 33639258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetic evaluation and test-retest reproducibility of [
    Finnema SJ; Nabulsi NB; Mercier J; Lin SF; Chen MK; Matuskey D; Gallezot JD; Henry S; Hannestad J; Huang Y; Carson RE
    J Cereb Blood Flow Metab; 2018 Nov; 38(11):2041-2052. PubMed ID: 28792356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding of the synaptic vesicle radiotracer [
    Smart K; Liu H; Matuskey D; Chen MK; Torres K; Nabulsi N; Labaree D; Ropchan J; Hillmer AT; Huang Y; Carson RE
    J Cereb Blood Flow Metab; 2021 May; 41(5):1067-1079. PubMed ID: 32757741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synaptic vesicle glycoprotein 2A (SV2A) levels in the cerebral cortex in patients with Alzheimer's disease: a radioligand binding study in postmortem brains.
    Mikkelsen JD; Kaad S; Aripaka SS; Finsen B
    Neurobiol Aging; 2023 Sep; 129():50-57. PubMed ID: 37269646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temporal and spatial changes in synaptic vesicle glycoprotein 2A (SV2A) under kainic acid induced epileptogenesis: An autoradiographic study.
    Pazarlar BA; Madsen CA; Oyar EÖ; Eğilmez CB; Mikkelsen JD
    Epilepsy Res; 2022 Jul; 183():106926. PubMed ID: 35526328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates.
    Li S; Cai Z; Wu X; Holden D; Pracitto R; Kapinos M; Gao H; Labaree D; Nabulsi N; Carson RE; Huang Y
    ACS Chem Neurosci; 2019 Mar; 10(3):1544-1554. PubMed ID: 30396272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluating the In Vivo Specificity of [
    Serrano ME; Becker G; Bahri MA; Seret A; Mestdagh N; Mercier J; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Molecules; 2019 May; 24(9):. PubMed ID: 31052478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET.
    Mecca AP; Chen MK; O'Dell RS; Naganawa M; Toyonaga T; Godek TA; Harris JE; Bartlett HH; Zhao W; Nabulsi NB; Wyk BCV; Varma P; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    Alzheimers Dement; 2020 Jul; 16(7):974-982. PubMed ID: 32400950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantifying SV2A density and drug occupancy in the human brain using [
    Koole M; van Aalst J; Devrome M; Mertens N; Serdons K; Lacroix B; Mercier J; Sciberras D; Maguire P; Van Laere K
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):396-406. PubMed ID: 30121895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [
    Toyonaga T; Khattar N; Wu Y; Lu Y; Naganawa M; Gallezot JD; Matuskey D; Mecca AP; Pittman B; Dias M; Nabulsi NB; Finnema SJ; Chen MK; Arnsten A; Radhakrishnan R; Skosnik PD; D'Souza DC; Esterlis I; Huang Y; van Dyck CH; Carson RE
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1012-1022. PubMed ID: 37955791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [
    Vogler L; Ballweg A; Bohr B; Briel N; Wind K; Antons M; Kunze LH; Gnörich J; Lindner S; Gildehaus FJ; Baumann K; Bartenstein P; Boening G; Ziegler SI; Levin J; Zwergal A; Höglinger GU; Herms J; Brendel M
    Neuroimage Clin; 2023; 39():103484. PubMed ID: 37541098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-in-Human Evaluation of
    Naganawa M; Li S; Nabulsi N; Henry S; Zheng MQ; Pracitto R; Cai Z; Gao H; Kapinos M; Labaree D; Matuskey D; Huang Y; Carson RE
    J Nucl Med; 2021 Apr; 62(4):561-567. PubMed ID: 32859701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Aβ deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [
    O'Dell RS; Mecca AP; Chen MK; Naganawa M; Toyonaga T; Lu Y; Godek TA; Harris JE; Bartlett HH; Banks ER; Kominek VL; Zhao W; Nabulsi NB; Ropchan J; Ye Y; Vander Wyk BC; Huang Y; Arnsten AFT; Carson RE; van Dyck CH
    Alzheimers Res Ther; 2021 Jan; 13(1):11. PubMed ID: 33402201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synaptic Terminal Density Early in the Course of Schizophrenia: An In Vivo UCB-J Positron Emission Tomographic Imaging Study of SV2A.
    Onwordi EC; Whitehurst T; Shatalina E; Mansur A; Arumuham A; Osugo M; Marques TR; Jauhar S; Gupta S; Mehrotra R; Rabiner EA; Gunn RN; Natesan S; Howes OD
    Biol Psychiatry; 2024 Apr; 95(7):639-646. PubMed ID: 37330164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics and 28-day test-retest repeatability and reproducibility of [
    Tuncel H; Boellaard R; Coomans EM; de Vries EF; Glaudemans AW; Feltes PK; García DV; Verfaillie SC; Wolters EE; Sweeney SP; Ryan JM; Ivarsson M; Lynch BA; Schober P; Scheltens P; Schuit RC; Windhorst AD; De Deyn PP; van Berckel BN; Golla SS
    J Cereb Blood Flow Metab; 2021 Jun; 41(6):1338-1350. PubMed ID: 34013797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal Characterization of mGluR5 Using
    Bertoglio D; Kosten L; Verhaeghe J; Thomae D; Wyffels L; Stroobants S; Wityak J; Dominguez C; Mrzljak L; Staelens S
    J Nucl Med; 2018 Nov; 59(11):1722-1727. PubMed ID: 29794227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [(11)C]UCB-A, a novel PET tracer for synaptic vesicle protein 2A.
    Estrada S; Lubberink M; Thibblin A; Sprycha M; Buchanan T; Mestdagh N; Kenda B; Mercier J; Provins L; Gillard M; Tytgat D; Antoni G
    Nucl Med Biol; 2016 Jun; 43(6):325-32. PubMed ID: 27260773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.